Google to pursue new biomarker study; Lantheus Holdings, T2 Biosystems set IPO terms;

> Google ($GOOG) plans to search for biomarkers as part of its new Baseline Study initiative, which will involve the use of Google experimental wearable devices to collect urine, blood, saliva and tears. Story

> Boston University scientists said they've found another potential new biomarker for Alzheimer's disease--variants in the gene PLXNA4--that may point to an increased risk. Story

> Lantheus Holdings, a seller of medical imaging agents used to diagnose cardiovascular diseases, was expected to trigger its IPO this week with a share price range between $12 and $15. Plans calls for raising as much as $125 million. Item

> Molecular diagnostics outfit T2 Biosystems set a price range for its pending IPO of between $15 and $17 per share. Story (reg. req.)

> CareDx said it has generated promising new results demonstrating the utility of its diagnostic technology to screen for symptoms of heart transplant rejection. Release

> Qiagen ($QGEN) and AstraZeneca ($AZN) will co-develop and sell a liquid biopsy-based companion diagnostic to be paired with Iressa, AstraZeneca's targeted treatment for non-small cell lung cancer. Release

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.